1. Introduction
===============

Diabetes mellitus (DM) is a common metabolic disease, its incidence is increasing year by year, and various complications seriously affect the quality of life of patients and are even life-threatening. Adult diabetes is expected to reach 439 million by 2030, accounting for 7.7% of the adult population.^\[[@R1],[@R2]\]^

Type 2 diabetes mellitus (T2DM) specifically refers to the glucose and fat metabolic disorder syndrome caused by insulin resistance (IR) and insufficient insulin secretion, accounting for more than 90% of the total number of diabetes.^\[[@R3],[@R4]\]^ IR refers to the decreased sensitivity of insulin to peripheral target tissues such as liver, muscle, and adipose tissue, insulin-induced glucose uptake and utilization efficiency, resulting in a series of clinical manifestations such as hyperglycemia, hyperinsulinemia, and dyslipidemia. IR is also considered to be a contributing factor to T2DM.^\[[@R5]\]^ The development of effective, low-toxic drugs for IR is important for the control of T2DM.

For the treatment, the Homeostatic Model Assessment for IR (HOMA-IR) is used as a standard for evaluating the degree of IR.^\[[@R6],[@R7]\]^ The drugs that improve T2DM with IR mainly include sulfonylureas,^\[[@R8]\]^ biguanides,^\[[@R9]\]^ Alpha-glucosidase inhibitors,^\[[@R10]\]^ thiazolidinediones,^\[[@R11]\]^ but are often accompanied by many adverse reactions such as edema, cardiovascular disease, and liver and kidney dysfunction. Berberine (BBR) is the main component of Coptis, with low toxicity and low cost. At present, the role of berberine in regulating and improving glycolipid metabolism has been confirmed.^\[[@R12]--[@R14]\]^ There are also many studies showing that BBR can effectively improve T2DM with IR,^\[[@R15]--[@R17]\]^ but it lacks relevant meta-analysis. This study aimed to systematically evaluate the efficacy and safety of BBR treatment with T2DM with IR using a meta-analysis method to provide the best evidence for its clinical application.

2. Methods
==========

The protocol has been registered on PROSPERO as CRD42019123225 (<https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=123225>). The protocol is written in accordance with the Systematic Review and Meta-analysis Program (PRISMA-P) Statement. If necessary, we will describe the changes in the full review.

2.1. Inclusion criteria for study selection
-------------------------------------------

### 2.1.1. Types of studies

Randomized controlled trials (RCTs) of BBR for the treatment of T2DM with IR will be included in the research, with language limited to Chinese and English. Observational studies, nonrandomized controlled studies, case report will be excluded.

### 2.1.2. Types of participants

Patients diagnosed with T2DM with IR will be included, while age, gender, region, ethnicity, and source are not restricted.

### 2.1.3. Types of interventions

The treatment group will use the BBR, with no limitation of the dose and frequency of the medicine. At the same time, the control group will use placebo for intervention. The trial period requires more than 1 course of treatment.

### 2.1.4. Types of outcome measures

#### 2.1.4.1. Primary outcomes

We use HOMA-IR as the primary outcome of T2DM with IR.

#### 2.1.4.2. Secondary outcomes

We also focus on the patient\'s blood glucose levels and all adverse reactions that occur during medication.

2.2. Search methods for the identification of studies
-----------------------------------------------------

### 2.2.1. Electronic searches

Literature research will be divided into 2 parts: electronic search and manual search. We will search PubMed, EMBASE, The Cochrane Library, the China National Knowledge Infrastructure, China Biology Medicine disc, the China Science and Technology Journal database, and the Wanfang database online. We will select the eligible studies published up to March 31, 2019. The search terms used in the systematic review are as follows: Berberine, BBR, Type 2 diabetes mellitus with insulin resistance, Type 2 diabetes mellitus, insulin resistance, T2DM with IR, T2DM, and IR.

The specific search strategy will be (taking PubMed as an example):

Search ((((Type 2 diabetes mellitus with insulin resistance \[Title/Abstract\] OR Type 2 diabetes mellitus \[Title/Abstract\] OR Insulin resistance \[Title/Abstract\] OR T2DM with IR \[Title/Abstract\] OR T2DM \[Title/Abstract\] OR IR \[Title/Abstract\]))) AND (Berberine \[Title/Abstract\] OR BBR\[Title/Abstract\]))

And a similar search strategy will be applied to other electronic databases.

### 2.2.2. Searching other resources

Dissertations, conference papers, ongoing trials, internal reports, etc., are searched by manual search methods. At the same time, we will also retrieve ongoing trials related to T2DM with IR from the clinical registration platform, such as the WHO International Clinical Trial Registry Platform. And we will also try to contact the test leader for further information if necessary.

2.3. Data collection and analysis
---------------------------------

### 2.3.1. Selection of studies

First, 2 reviewers will independently read the titles of the references to exclude the obviously irrelevant literatures, and then they will read the abstract and full text to determine whether the studies would be finally included. EndNote X7 literature management software will be used for the screening process. And the reviewers will contact the author for the complete information if needed. If there is a disagreement, another reviewer will decide it. And we will also record the exclusion reason for the excluded literature. The details of selection process will be shown in the PRISMA flow chart (Fig. [1](#F1){ref-type="fig"}).

![The PRISMA flow chart. PRISMA = preferred reporting items for systematic reviews and meta-analyses.](medi-98-e16947-g001){#F1}

### 2.3.2. Data extraction and management

Two reviewers will retrieve the following data independently: study details (authors, country, year of publication, multicenter study, or not), participant details (baseline data, diagnostic criteria), the methods used (sample size, blinding method), the interventions used in both treatment and control group, the primary and secondary outcomes (HOMA-IR, blood glucose levels, adverse events). And we will contact the corresponding authors for the data mentioned above if the data is incomplete. And if there is a disagreement, all reviewers will join the discussion to deal with it.

### 2.3.3. Assessment of risk of bias in included studies

Two reviewers will assess the quality of each article independently using the risk of bias (ROB) assessment tool in the Cochrane. Random sequence generation, allocation concealment, blindness assessment of results, incomplete outcome data, selective reporting, and other biases will be all evaluated. The results will be: low-risk, unclear, and high-risk. If there is a disagreement, a group discussion will be conducted to make a decision.

### 2.3.4. Measures of treatment effect

For continuous variable outcomes, we will record the mean difference (MD) or standardized mean difference (SMD) and 95% confidence interval (CI). And we will record the relative risk (RR) and 95% CI for dichotomous outcomes.

### 2.3.5. Dealing with missing data

If the information of the article is missing, we will contact the author for further information. If the necessary information is not obtained, we will use the available data for data synthesis. And we will also discuss the possible consequences of missing data.

### 2.3.6. Assessment of heterogeneity

*I*^2^ will be used to determine the heterogeneity. When *I*^2^ ≤ 50%, heterogeneity is considered acceptable. And when *I*^2^ \> 50%, the heterogeneity among the trials will be considered significant, and further subgroup analysis would be conducted to identify possible causes.

### 2.3.7. Data synthesis and analysis

We will use Review Manager software (RevMan V.5.3.5) provided by Cochrane

Collaboration for data synthesis and analysis. When *I*^2^ ≤ 50%, a fixed-effects model will be used to calculate the RR and MD; on the contrary, we will use a random-effects model. If the heterogeneity is significant, we will analyze the cause of the heterogeneity by subgroup analysis or meta regression analysis.

### 2.3.8. Assessment of publication bias

We will use a funnel plot to judge whether a publication bias exists when at least 10 trials are included in the research. And when the number is less than 10, the publication bias assessment will be determined by STATA 13.0.

### 2.3.9. Subgroup analysis

Subgroup analysis is to explore the source of heterogeneity. When more than 10 studies are included, subgroup analyses can be performed according to interventions, participants, age, gender, duration of disease, and dose.

### 2.3.10. Sensitivity analysis

Sensitivity analysis will be performed to examine the robustness of conclusions. We will re-analyze whether the conclusions have changed by determining the effects of excluding studies with high risks of bias, studies with missing data, and outliers.

### 2.3.11. Grading the quality of evidence

It is recommended to use the Grading of Recommendations Assessment, Development and Evaluation (GRADE)^\[[@R18]\]^ to analyze the quality level of evidence. Bias risks; heterogeneity; publication bias and other factors will be considered. The quality of the evidence will be graded using "very low," "low," "moderate," or "high."

3. Discussion
=============

IR is the main mechanism of T2DM pathogenesis and runs through the whole process of T2DM, and related studies have confirmed that IR is closely related to the progress of complications of DM.^\[[@R19],[@R20]\]^

The main mechanism by which BBR improves IR is by inhibiting the function of mitochondria, accelerating the breakdown of glycogen, and activating the AMPK signaling pathway.^\[[@R21],[@R22]\]^ Although BBR has been shown to be effective in T2DM with IR by multiple trials, its safety and efficacy are not systematically evaluated, so it is necessary to systematically evaluate the published RCTs to provide evidence-based medical evidence for their clinical use. The process of performing this systematic review, as shown in Fig. [2](#F2){ref-type="fig"}, includes identification of studies, selection of studies, data extraction and management, and data analysis.

![Flow diagram of the systematic review and meta-analysis.](medi-98-e16947-g002){#F2}

Nevertheless, this review still has some limitations. First, there is a certain language bias in this study, which only includes Chinese and English. Second, due to the different doses of BBR, there may be significant heterogeneity here. Finally, small sample size tests may lead to a higher risk bias.
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